Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23506639 | 0.77 | MAPT (0.53) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL3157871 | 0.77 | HTR1B (0.63) | MEN1KMT2AKIF11 | |
| SCHEMBL5804213 | 0.76 | MAPT (0.51) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL5804215 | 0.76 | MAPT (0.51) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL11588828 | 0.75 | MAPT (0.49) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL4778907 | 0.75 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL2515756 | 0.75 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL1465735 | 0.75 | F2 (0.60) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL6826753 | 0.75 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2GFER | |
| SCHEMBL6982857 | 0.75 | F2 (0.60) | MAPTMEN1KMT2ASMN1; SMN2GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396278-A | Carbazole derivatives as dopamine D3 receptor selectivity modulators | 北京大学 | 2023-07-07 | — | — | CN | disclosed |
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6514981-B1 | By contacting cells expressing said protein tyrosine kinase with compound | SUGEN, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | MAPT 1673/4885MEN1 3806/4885KMT2A 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.